(Q86564392)

English

PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage

scientific article published on 21 October 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Jyoti D Patel

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Mark A Socinski

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Edward B Garon

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Craig H Reynolds

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

David R Spigel

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Mark R Olsen

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Robert C Hermann

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Robert M Jotte

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Thaddeus Beck

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Donald A Richards

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Susan C Guba

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Jingyi Liu

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Bente Frimodt-Moller

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

William J John

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Coleman K Obasaju

15

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Eduardo J Pennella

16

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Philip Bonomi

17

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Ramaswamy Govindan

18

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

publication date

21 October 2013

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

31

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

34

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

4349-4357

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/24145346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24145346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tables of the number of patients required in clinical trials using the logrank test.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24145346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24145346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab in non small cell lung cancer: development, current status and issues

1 reference

https://pubmed.ncbi.nlm.nih.gov/24145346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel

1 reference

https://pubmed.ncbi.nlm.nih.gov/24145346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24145346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24145346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24145346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24145346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://pubmed.ncbi.nlm.nih.gov/24145346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24145346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, r

1 reference

https://pubmed.ncbi.nlm.nih.gov/24145346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

1 reference

https://pubmed.ncbi.nlm.nih.gov/24145346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24145346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24145346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2012.47.9626

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145346%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q86564392&oldid=1568133404"